Unjha Formulations Ltd.
Snapshot View

10.40 +0.30 ▲3.0%

03 August 2021, 03:16:00 P.M.
Volume: 1,187

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website
Financial Indicators
Market Cap 4.53 Cr.
Earnings per share (EPS) 0.23 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 43.51 Trailing Twelve Months Ending 2021-03
Industry PE 32.66 Trailing Twelve Months Ending 2021-03
Book Value / Share 10.44 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.97 Calculated using Price: 10.10
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.45 Cr. 4,480,500 Shares
FaceValue 10
Company Profile

Unjha Formulations (U-For), incorporated in 1987, is the sister concern of Urvesh Psyllium Industries Limited. U-For is the pharmaceuticals manufacturing unit, which is going to various category of formulation like tablet, capsule, oral liquids, injectables (SVP) and powder section to manufacture ayurvedic as well as allopathy products.

Fibron Powder & Fibron Sugar Free Powder are the branded ayurvedic products of the company, based on psyllium husk. The products met with an overwhelming success in our domestic market. The products mainly caters to somewhat sophisticated market segment who is conscious about their health and at the same time are very particular about various flavour like Orange, Lemon, Lime & Mango taste of the product.

Fibron Powder & Fibron SF powder offer excellent value for the money. Speed U - for could able to promote Fibron Powder & Fibron Powder SF at a most competitive price without sacrificing on quality mainly because their sister concern unit Urvesh Psyllium Industries Ltd. is one of the largest raw material supplier and processor of plyllium in the world. It may be important to note here that even Glaxo India Ltd, Proctor & Gamble, Nicholas Piramal India Ltd are the company's most valued costumers.

The company has entered into an agreement with Nicholas Piramal India for sale of Isabgol Husk based product `Tybogel` and Morepen Laboratories for sale of Dr.Mopren Sat Isabgol.

Urvesh Psyllium Industries Limited is the leading processor and exporter of Psyllium Husk & Powder in India.The company is in this line of business since last 52 years (i.e. from 1949). Initially it processed and supplied Psyllium products in local market but, looking to the worldwide demand, in 1966 it started to export Psyllium Products in the name of Rajendra Brothers. Later on with the increase of demand from overseas buyers there rose a need to expand the business, and thus Urvesh Psyllium Industries was formed in 1985, which later on was converted into a Limited Company in the year 1995.

Product range of the company includes:

  • Fibron Powder
  • Fibron Sugar Free Powder
  • Psyllium Capsules

Achievements/ recognition:

  • GMP & ISO:9001-2000 certified unit.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.97%
1 Week
-3.70%
1 Month
-5.54%
3 Month
+27.76%
6 Month
+4.00%
1 Year
+62.50%
2 Year
+18.86%
5 Year
+55.22%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 57.28 244.18 89.75 52.48 31.18 24.22 18.57
Return on Capital Employed (%) 8.75 68.66 73.70 67.61 32.15 25.41 25.57
Return on Assets (%) 2.11 3.50 3.84 4.92 8.26 8.82 6.79 7.89 8.37

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 0 0 0 0 1 1 1 2 2
Non Curr. Liab. 0
Curr. Liab. 2 3 4 3 2 3 3 2 2
Minority Int.
Equity & Liab. 3 3 4 3 3 4 4 4 4
Non Curr. Assets 1 1 1 1 1 1 1 1 1
Curr. Assets 1 1 2 2 2 2 3 3 3
Misc. Exp. not W/O 0 0 0 0 0 0 0
Total Assets 3 3 4 3 3 4 4 4 4

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 6 5 7 9 10 12 11 11 11
Other Income 0 0 0 0 0 0 0
Total Income 6 5 7 9 10 12 11 12 11
Total Expenditure -6 -5 -6 -9 -10 -12 -11 -11 -10
PBIDT 0 0 0 0 0 0 0 0 1
Interest 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Taxation
Exceptional Items
PAT 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 2 0 1 -1 0 0 0 0 0
Cash Fr. Inv. 0 0 0 0 0 0 0 0 0
Cash Fr. Finan. -2 0 0 0 0 0 0 0
Net Change 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 1 0 0 0 0 1 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 36.92 36.92 36.92 36.92 36.92 36.92 36.92 36.92 36.92
Public 63.08 63.08 63.08 63.08 63.08 63.08 63.08 63.08 63.08
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
Reg. 34 (1) Annual Report
Subject: Annual Report for FY 2020-21
Ref. : Regulation 34(1) of SEBI (LODR) Regulations 2015
Tue, 27 Jul 2021
Notice Of 27Th Annual General Meeting
Regulation 30 (LODR)
Tue, 27 Jul 2021
Sub : Published Notice Of AGM In - Free Press -English/ Lok Mitra Gujarati.<BR> <BR>
Compliance with Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015

Technical Scans View Details

Mon, 02 Aug 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Week Low Close Crossing Last Week Low
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 795.15 +2.7%
Divi's Laboratories Ltd. 130,822.92 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,722.95 +0.4%
Cipla Ltd. 74,356.30 929.00 +0.8%
Cadila Healthcare Ltd. 60,574.85 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,092.60 +1.1%
Piramal Enterprises Ltd. 56,317.82 2,504.45 +0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 795.15 +2.7%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,722.95 +0.4%
Cipla Ltd. Consolidated 2021-03 30.92 929.00 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,092.60 +1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,504.45 +0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 795.15 +2.7%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,722.95 +0.4%
Cipla Ltd. Consolidated 2021-03 4.06 929.00 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,092.60 +1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,504.45 +0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 795.15 +2.7%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,722.95 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 929.00 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,092.60 +1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,504.45 +0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 795.15 +2.7%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,722.95 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 929.00 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,092.60 +1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,504.45 +0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 795.15 +2.7%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,722.95 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 929.00 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,092.60 +1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,504.45 +0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 795.15 +2.7%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,722.95 +0.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 929.00 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,092.60 +1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,504.45 +0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 795.15 +2.7%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 5,008.85 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,722.95 +0.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 929.00 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.30 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,092.60 +1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,504.45 +0.6%